Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
October 24 2024 - 7:30AM
Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a
late-stage biopharmaceutical company focused on developing and
commercializing products to treat rare diseases where there is an
unmet medical need, today announced that it will be participating
in The ThinkEquity Conference on October 30, 2024, at the Mandarin
Oriental Hotel in New York. The ThinkEquity Conference gathers
institutional investors, corporate clients, and other industry
professionals to highlight groundbreaking innovations and financial
strategies.
Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief
Financial Officer of Soligenix, will be presenting at 9:00 AM ET on
October 30th. Members of Soligenix management will also be holding
one-on-one investor meetings throughout the day. Interested
investors can register to attend and schedule on-on-one meetings
here.
About ThinkEquity
ThinkEquity is a boutique investment bank
founded by professionals who have collaborated for over a decade,
collectively financing over $50 billion in public and private
capital raises, restructurings, and mergers and acquisitions. Past
ThinkEquity conferences have featured over 70 company
presentations, 700+ attendees, and 500+ one-on-one meetings,
providing a valuable platform for companies and investors to
connect. To register to attend The ThinkEquity Conference, please
follow this link.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing and moving toward
potential commercialization of HyBryte™ (SGX301 or synthetic
hypericin sodium) as a novel photodynamic therapy utilizing safe
visible light for the treatment of cutaneous T-cell lymphoma
(CTCL). With successful completion of the second Phase 3 study,
regulatory approvals will be sought to support potential
commercialization worldwide. Development programs in this business
segment also include expansion of synthetic hypericin (SGX302) into
psoriasis, our first-in-class innate defense regulator (IDR)
technology, dusquetide (SGX942) for the treatment of inflammatory
diseases, including oral mucositis in head and neck cancer, and
(SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes
development programs for RiVax®, our ricin toxin vaccine candidate,
as well as our vaccine programs targeting filoviruses (such as
Marburg and Ebola) and CiVax™, our vaccine candidate for the
prevention of COVID-19 (caused by SARS-CoV-2). The development of
our vaccine programs incorporates the use of our proprietary heat
stabilization platform technology, known as ThermoVax®. To date,
this business segment has been supported with government grant and
contract funding from the National Institute of Allergy and
Infectious Diseases (NIAID), the Defense Threat Reduction Agency
(DTRA) and the Biomedical Advanced Research and Development
Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company’s website at https://www.soligenix.com and follow us on
LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking
statements that reflect Soligenix's current expectations about its
future results, performance, prospects and opportunities, including
but not limited to, potential market sizes, patient populations,
clinical trial enrollment, the expected timing for closing the
offering described herein and the intended use of proceeds
therefrom. Statements that are not historical facts, such as
"anticipates," "estimates," "believes," "hopes," "intends,"
"plans," "expects," "goal," "may," "suggest," "will," "potential,"
or similar expressions, are forward-looking statements. These
statements are subject to a number of risks, uncertainties and
other factors that could cause actual events or results in future
periods to differ materially from what is expressed in, or implied
by, these statements, and include the expected amount and use of
proceeds from the offering and the expected closing date of the
offering. Soligenix cannot assure you that it will be able to
successfully develop, achieve regulatory approval for or
commercialize products based on its technologies, particularly in
light of the significant uncertainty inherent in developing
therapeutics and vaccines against bioterror threats, conducting
preclinical and clinical trials of therapeutics and vaccines,
obtaining regulatory approvals and manufacturing therapeutics and
vaccines, that product development and commercialization efforts
will not be reduced or discontinued due to difficulties or delays
in clinical trials or due to lack of progress or positive results
from research and development efforts, that it will be able to
successfully obtain any further funding to support product
development and commercialization efforts, including grants and
awards, maintain its existing grants which are subject to
performance requirements, enter into any biodefense procurement
contracts with the U.S. Government or other countries, that it will
be able to compete with larger and better financed competitors in
the biotechnology industry, that changes in health care practice,
third party reimbursement limitations and Federal and/or state
health care reform initiatives will not negatively affect its
business, or that the U.S. Congress may not pass any legislation
that would provide additional funding for the Project BioShield
program. In addition, there can be no assurance as to the timing or
success of any of its clinical/preclinical trials. Despite the
statistically significant result achieved in the first HyBryte™
(SGX301) Phase 3 clinical trial for the treatment of cutaneous
T-cell lymphoma, there can be no assurance that the second HyBryte™
(SGX301) Phase 3 clinical trial will be successful or that a
marketing authorization from the FDA or EMA will be granted.
Additionally, although the EMA has agreed to the key design
components of the second HyBryte™ (SGX301) Phase 3 clinical trial,
no assurance can be given that the Company will be able to modify
the development path to adequately address the FDA's concerns or
that the FDA will not require a longer duration comparative study.
Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3
clinical trial for the treatment of cutaneous T-cell lymphoma and
the Phase 2a clinical trial of SGX302 for the treatment of
psoriasis, there can be no assurance as to the timing or success of
the clinical trials of SGX302 for the treatment of psoriasis.
Further, there can be no assurance that RiVax® will qualify for a
biodefense Priority Review Voucher (PRV) or that the prior sales of
PRVs will be indicative of any potential sales price for a PRV for
RiVax®. Also, no assurance can be provided that the Company will
receive or continue to receive non-dilutive government funding from
grants and contracts that have been or may be awarded or for which
the Company will apply in the future. These and other risk factors
are described from time to time in filings with the Securities and
Exchange Commission (the "SEC"), including, but not limited to,
Soligenix's reports on Forms 10-Q and 10-K. Unless required by law,
Soligenix assumes no obligation to update or revise any
forward-looking statements as a result of new information or future
events.
Soligenix, Inc. Contact Information
Jonathan Guarino, CPA, CGMASenior Vice President and Chief
Financial Officer (609) 538-8200 | www.soligenix.com
Soligenix, Inc.29 Emmons Drive, Suite B-10Princeton, NJ
08540
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Dec 2023 to Dec 2024